Vicuron To File Anidulafungin For Invasive Candidiasis Under Separate NDA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Vicuron’s revised regulatory strategy for anidulafungin involves filing a separate NDA for treatment of invasive candidiasis/candidemia and addressing other concerns through labeling discussions.